|
2024-03-05 |
2024-03-04 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
840
-0.5%
16,01
13 448
USD
|
840
-0.5%
|
16,01
|
13 448
USD
|
|
|
2024-03-05 |
2024-03-04 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 217
-0.5%
16,01
19 484
USD
|
1 217
-0.5%
|
16,01
|
19 484
USD
|
|
|
2024-03-05 |
2024-03-01 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
1 679
-1.0%
16,03
26 909
USD
|
1 679
-1.0%
|
16,03
|
26 909
USD
|
|
|
2024-03-05 |
2024-03-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 107
-0.8%
16,03
33 769
USD
|
2 107
-0.8%
|
16,03
|
33 769
USD
|
|
|
2024-02-29 |
2024-02-28 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 303
-0.9%
16,14
37 177
USD
|
2 303
-0.9%
|
16,14
|
37 177
USD
|
|
|
2024-02-29 |
2024-02-28 |
V
Vente
|
Leonard Frank X
EVP, Pres., Novocure Oncology
Dirigeant
|
2 078
-1.3%
16,14
33 545
USD
|
2 078
-1.3%
|
16,14
|
33 545
USD
|
|
|
2023-11-08 |
2023-11-07 |
VP
Vente planifiée
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
382
-0.3%
12,65
4 832
USD
|
382
-0.3%
|
12,65
|
4 832
USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
294
-0.1%
21,82
6 414
USD
|
294
-0.1%
|
21,82
|
6 414
USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
273
-0.2%
21,82
5 956
USD
|
273
-0.2%
|
21,82
|
5 956
USD
|
|
|
2023-09-05 |
2023-09-01 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
883
-0.9%
21,82
19 265
USD
|
883
-0.9%
|
21,82
|
19 265
USD
|
|
|
2023-08-04 |
2023-08-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
1 144
-1.1%
30,25
34 607
USD
|
1 144
-1.1%
|
30,25
|
34 607
USD
|
|
|
2023-03-07 |
2023-03-07 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 315
-4.1%
75,59
174 999
USD
|
2 315
-4.1%
|
75,59
|
174 999
USD
|
|
|
2023-03-07 |
2023-03-07 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
6 003
-9.6%
75,00
450 206
USD
|
6 003
-9.6%
|
75,00
|
450 206
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
20 415
-8.9%
76,16
1 554 794
USD
|
20 415
-8.9%
|
76,16
|
1 554 794
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 692
-0.7%
76,16
128 862
USD
|
1 692
-0.7%
|
76,16
|
128 862
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
3 528
-1.5%
76,16
268 690
USD
|
3 528
-1.5%
|
76,16
|
268 690
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
16 909
-11.9%
76,16
1 287 779
USD
|
16 909
-11.9%
|
76,16
|
1 287 779
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
2 942
-2.0%
76,16
224 061
USD
|
2 942
-2.0%
|
76,16
|
224 061
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
1 570
-1.1%
76,16
119 570
USD
|
1 570
-1.1%
|
76,16
|
119 570
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
593
-0.9%
76,16
45 163
USD
|
593
-0.9%
|
76,16
|
45 163
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
775
-0.8%
76,16
59 024
USD
|
775
-0.8%
|
76,16
|
59 024
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
4 730
-4.4%
76,16
360 234
USD
|
4 730
-4.4%
|
76,16
|
360 234
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
888
-1.4%
76,16
67 630
USD
|
888
-1.4%
|
76,16
|
67 630
USD
|
|
|
2023-03-07 |
2023-03-03 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
4 403
-6.5%
76,16
335 330
USD
|
4 403
-6.5%
|
76,16
|
335 330
USD
|
|
|
2023-03-06 |
2023-03-03 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 059
-2.9%
77,64
159 859
USD
|
2 059
-2.9%
|
77,64
|
159 859
USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
281
-0.4%
75,28
21 153
USD
|
281
-0.4%
|
75,28
|
21 153
USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
1 213
-0.7%
75,28
91 312
USD
|
1 213
-0.7%
|
75,28
|
91 312
USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
1 055
-1.1%
75,28
79 418
USD
|
1 055
-1.1%
|
75,28
|
79 418
USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
937
-0.9%
75,28
70 535
USD
|
937
-0.9%
|
75,28
|
70 535
USD
|
|
|
2023-03-06 |
2023-03-02 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
844
-1.4%
75,28
63 535
USD
|
844
-1.4%
|
75,28
|
63 535
USD
|
|
|
2023-03-03 |
2023-03-02 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
308
-0.5%
76,05
23 424
USD
|
308
-0.5%
|
76,05
|
23 424
USD
|
|
|
2023-03-03 |
2023-03-02 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
3 799
-6.0%
75,32
286 154
USD
|
3 799
-6.0%
|
75,32
|
286 154
USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
2 164
-1.2%
76,36
165 248
USD
|
2 164
-1.2%
|
76,36
|
165 248
USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
1 684
-2.6%
76,36
128 594
USD
|
1 684
-2.6%
|
76,36
|
128 594
USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Shah Pritesh
Chief Growth Officer
Dirigeant
|
1 923
-1.9%
76,36
146 845
USD
|
1 923
-1.9%
|
76,36
|
146 845
USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
2 198
-2.2%
76,36
167 845
USD
|
2 198
-2.2%
|
76,36
|
167 845
USD
|
|
|
2023-03-02 |
2023-03-01 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
755
-1.1%
76,36
57 654
USD
|
755
-1.1%
|
76,36
|
57 654
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 183
-13.5%
120,00
861 960
USD
|
7 183
-13.5%
|
120,00
|
861 960
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 183
-13.5%
114,00
818 863
USD
|
7 183
-13.5%
|
114,00
|
818 863
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
5 517
-10.7%
108,00
595 836
USD
|
5 517
-10.7%
|
108,00
|
595 836
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 500
-14.0%
108,00
810 000
USD
|
7 500
-14.0%
|
108,00
|
810 000
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
7 826
-14.5%
108,00
845 208
USD
|
7 826
-14.5%
|
108,00
|
845 208
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
1 010
-2.1%
117,00
118 170
USD
|
1 010
-2.1%
|
117,00
|
118 170
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
526
-1.1%
115,03
60 508
USD
|
526
-1.1%
|
115,03
|
60 508
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
417
-0.9%
108,00
45 036
USD
|
417
-0.9%
|
108,00
|
45 036
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
2 345
-4.6%
119,01
279 073
USD
|
2 345
-4.6%
|
119,01
|
279 073
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Weinberg Uri
Chief Science Officer
Dirigeant
|
1 201
-2.7%
120,00
144 120
USD
|
1 201
-2.7%
|
120,00
|
144 120
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Weinberg Uri
Chief Science Officer
Dirigeant
|
2 617
-5.6%
108,00
282 636
USD
|
2 617
-5.6%
|
108,00
|
282 636
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Weinberg Uri
Chief Science Officer
Dirigeant
|
1 946
-4.0%
120,00
233 520
USD
|
1 946
-4.0%
|
120,00
|
233 520
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Weinberg Uri
Chief Science Officer
Dirigeant
|
2 379
-4.8%
120,00
285 480
USD
|
2 379
-4.8%
|
120,00
|
285 480
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
187 500
-93.2%
108,00
20 250 000
USD
|
187 500
-93.2%
|
108,00
|
20 250 000
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
500
-3.6%
119,99
59 994
USD
|
500
-3.6%
|
119,99
|
59 994
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
1 344
-8.7%
119,35
160 405
USD
|
1 344
-8.7%
|
119,35
|
160 405
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
2 123
-12.1%
118,47
251 515
USD
|
2 123
-12.1%
|
118,47
|
251 515
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
999
-5.4%
117,01
116 894
USD
|
999
-5.4%
|
117,01
|
116 894
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
1 395
-7.0%
116,06
161 906
USD
|
1 395
-7.0%
|
116,06
|
161 906
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
3 702
-15.7%
115,21
426 512
USD
|
3 702
-15.7%
|
115,21
|
426 512
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
4 568
-16.2%
114,35
522 362
USD
|
4 568
-16.2%
|
114,35
|
522 362
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
2 000
-6.6%
112,86
225 726
USD
|
2 000
-6.6%
|
112,86
|
225 726
USD
|
|
|
2023-01-09 |
2023-01-05 |
VP
Vente planifiée
|
Danziger Asaf
Chief Executive Officer
Administrateur exécutif
|
8 369
-21.7%
111,23
930 916
USD
|
8 369
-21.7%
|
111,23
|
930 916
USD
|
|
|
2023-01-09 |
2023-01-05 |
V
Vente
|
Shah Pritesh
Chief Commercial Officer
Dirigeant
|
387
-0.5%
108,00
41 796
USD
|
387
-0.5%
|
108,00
|
41 796
USD
|
|
|
2022-10-17 |
2022-10-13 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
6 754
-13.4%
76,01
513 372
USD
|
6 754
-13.4%
|
76,01
|
513 372
USD
|
|
|
2022-10-07 |
2022-10-06 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
6 754
-11.8%
84,37
569 835
USD
|
6 754
-11.8%
|
84,37
|
569 835
USD
|
|
|
2022-09-26 |
2022-09-22 |
V
Vente
|
Leonard Frank X
President, CNS Cancers US
Dirigeant
|
6 754
-9.6%
77,00
520 058
USD
|
6 754
-9.6%
|
77,00
|
520 058
USD
|
|
|
2022-09-19 |
2022-09-15 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
5 517
-7.2%
90,00
496 530
USD
|
5 517
-7.2%
|
90,00
|
496 530
USD
|
|
|
2022-09-19 |
2022-09-15 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
6 754
-8.1%
87,31
589 692
USD
|
6 754
-8.1%
|
87,31
|
589 692
USD
|
|
|
2022-09-12 |
2022-09-09 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
1 863
-2.2%
88,00
163 944
USD
|
1 863
-2.2%
|
88,00
|
163 944
USD
|
|
|
2022-09-07 |
2022-09-06 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
1 384
-1.6%
78,57
108 741
USD
|
1 384
-1.6%
|
78,57
|
108 741
USD
|
|
|
2022-09-06 |
2022-09-02 |
V
Vente
|
Shah Pritesh
Chief Commercial Officer
Dirigeant
|
269
-0.3%
79,04
21 261
USD
|
269
-0.3%
|
79,04
|
21 261
USD
|
|
|
2022-09-06 |
2022-09-02 |
V
Vente
|
Burke William Patrick
Chief Human Resources Officer
Dirigeant
|
718
-1.3%
79,04
56 749
USD
|
718
-1.3%
|
79,04
|
56 749
USD
|
|
|
2022-09-06 |
2022-09-02 |
V
Vente
|
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
Dirigeant
|
296
-0.2%
79,04
23 395
USD
|
296
-0.2%
|
79,04
|
23 395
USD
|
|
|
2022-09-06 |
2022-09-02 |
V
Vente
|
Cordova Ashley
Chief Financial Officer
Dirigeant
|
885
-1.2%
79,04
69 948
USD
|
885
-1.2%
|
79,04
|
69 948
USD
|
|
|
2022-09-06 |
2022-09-02 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
584
-0.7%
79,04
46 158
USD
|
584
-0.7%
|
79,04
|
46 158
USD
|
|
|
2022-09-06 |
2022-09-01 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
48
-0.1%
78,96
3 790
USD
|
48
-0.1%
|
78,96
|
3 790
USD
|
|
|
2022-09-06 |
2022-09-01 |
V
Vente
|
Leonard Frank X
Chief Development Officer
Dirigeant
|
438
-0.5%
78,14
34 225
USD
|
438
-0.5%
|
78,14
|
34 225
USD
|
|
